Revenue Growth and Actual Profitability in a Procedural Facility Are Not the Same Measurement

Revenue growth and actual profitability measure different things in a physician-owned procedural facility. Revenue answers one question: how much did the facility collect? Actual profitability answers another: how much of that collection reflects sustainable margin after accounting for what it cost to produce each case. A facility can grow revenue every quarter for three years while moving away from profitability at the same time. The schedule does not show this. Neither does the P&L, read in isolation.

Why Revenue Is the Wrong Primary Metric for an Independent Procedural Facility

Revenue growth is visible, trackable, and feels like progress. More cases, higher reimbursement, a stronger procedure mix — each of these moves the top line in a direction that looks like improvement. However, revenue is the numerator of a fraction. The denominator is the full cost of producing that revenue, and in a physician-owned ASC or OBL, the denominator is where the complexity lives.

Two facilities with identical revenue figures can have profitability positions that differ by hundreds of thousands of dollars annually. The difference is not found in their schedules or their reimbursement rates. It lives in their cost structure — specifically in the commodity supply layer that runs beneath every case and reprices on cycles neither facility controls or actively benchmarks against peers. Revenue growth obscures this. A rising top line in an environment of rising costs can represent per-case margin compression, not genuine improvement in the facility’s financial position.

In practice, a physician-owner watching revenue grow quarter over quarter while per-case margin holds flat or falls is not witnessing business improvement. They are watching a facility run harder to hold its position. The distinction matters because the interventions required to address a revenue problem are entirely different from those required to address a cost position problem. Revenue growth cannot solve a structural cost gap.

The Profitability Metrics That Reveal What Revenue Conceals

The financial measurements that reflect actual profitability in a physician-owned procedural facility are not the ones that appear most prominently in standard monthly reporting. Per-case margin — what the facility retains after direct case costs are subtracted from reimbursement — is the number that shows whether the business is improving or simply growing. Moreover, per-case margin is the number most directly affected by the commodity supply cost position a facility holds relative to peer independent facilities.

A facility running 15% more cases this quarter than last has grown revenue. Whether it has improved profitability depends entirely on whether per-case margin held, improved, or compressed during the same period. If per-case margin compressed while volume grew, the facility added cases at a lower effective margin than it was previously achieving. That is volume absorbing a cost problem, not profitability growth.

According to VMG Health’s multi-specialty ASC benchmarking data, the average ASC allocates 26.3% of its operating budget to drugs and medical supplies. That is the cost category with the greatest variance between facilities at similar volume — and the category most independent facilities have never formally compared against what peer facilities pay for the same inputs. As examined in prior work on how drug and supply costs rise above market, this variance is rarely visible in revenue-focused reporting. It becomes visible only when per-case margin is tracked against a peer benchmark rather than against the facility’s own prior periods.

What Conflating Revenue and Profitability Costs Over Time

The practical consequence of measuring a facility’s health primarily through revenue is that it allows structural cost problems to compound undetected. Each quarter, the facility reports revenue. The top line looks acceptable. No one is prompted to ask whether the cost structure underneath it reflects market rates for comparable independent facilities. The assumption is that a growing revenue line means the business is healthy.

However, over 24 to 36 months, this assumption allows the gap between what the facility pays for commodity supplies and what the market bears to widen without correction. The gap does not appear in revenue reporting. It appears in per-case margin compression that becomes harder to explain as years pass. By the time it is fully legible, it has been compounding long enough that the distance between the facility’s current cost position and market rates for peer independent ASCs and OBLs is material.

Furthermore, revenue growth during this period makes the problem harder to see. A facility growing revenue 8% year over year while per-case margin falls 4% is losing ground on profitability while appearing to gain ground on performance. The two numbers tell different stories. Most independent procedural facilities are reading only one of them.

The Question Revenue Growth Cannot Answer

Revenue growth tells a physician-owner that the clinical operation is producing cases and that reimbursement is being collected. However, it does not tell them whether the profitability of each case reflects the facility’s market position on costs. Moreover, it does not tell them whether the per-case margin they are producing sits above, at, or below what comparable independent facilities at their volume and specialty mix are sustaining. And it does not tell them whether the cost structure underneath their revenue reflects what the market bears or what their distributor has been charging since the last contract renewal.

Those are profitability questions. Revenue answers none of them. For most independent physician-owned ASCs and OBLs, the profitability picture at the case level has never been evaluated against a peer benchmark that would make those answers available.

If you want to understand what your facility’s actual profitability position looks like relative to peer independent facilities, request your complimentary supply cost analysis at vantumpartners.com. You see your per-case cost position against documented peer pricing. No obligation.

Frequently Asked Questions

What is the difference between revenue growth and actual profitability in a physician-owned ASC or OBL?

Revenue growth measures how much the facility collects from cases performed. Actual profitability measures how much of that collection represents sustainable margin after accounting for the full cost of producing each case. A physician-owned ASC or OBL can grow revenue consistently while profitability declines, if the cost structure underneath that revenue rises faster than the top line. The two measurements answer different questions. Most independent procedural facilities prioritize the one that is easier to track.

Why can revenue growth mask declining profitability in an independent procedural facility?

Revenue growth masks declining profitability when cost increases at the case level distribute across enough line items that no single category produces a clear attribution. When commodity supply costs rise above market rates incrementally over 24 to 36 months, per-case margin compresses. However, if revenue also grows during the same period, the compression is harder to see in aggregate reporting. The facility appears to be improving. At the case level, it is losing margin. Revenue reporting does not separate these two conditions.

What metric most accurately reflects actual profitability in a physician-owned ASC?

Per-case margin — the amount the facility retains after direct case costs are subtracted from reimbursement — most accurately reflects actual profitability in a physician-owned ASC or OBL. Unlike revenue, per-case margin captures the relationship between what the facility earns and what it costs to produce that earnings at the individual case level. It is also the metric most directly affected by the facility’s commodity supply cost position relative to peer independent facilities, which is where the most significant profitability variance typically resides.

How does commodity supply cost position affect the difference between revenue and profitability in an ASC?

Commodity supply costs represent a direct per-case expense that reduces the margin retained on each procedure. When a facility’s commodity supply costs run above market rates for comparable independent facilities, every case produces less margin than it would at market pricing, regardless of the revenue that case generates. Two facilities with identical revenue per case can have profitability positions that differ materially. The difference is in their respective cost positions, not in their clinical volume or reimbursement rates.

How do I know if my ASC’s revenue growth is translating into actual profitability improvement?

Revenue growth translates into actual profitability improvement only when per-case margin holds or improves during the same period. If per-case margin compresses while revenue grows, the facility is adding volume at a lower effective margin than it previously achieved. Determining whether per-case margin sits at, above, or below what comparable independent facilities sustain at your volume and specialty mix requires a benchmark comparison against peer facility cost and margin data. That comparison does not exist inside your own financial reporting.